Evidence map›Paper›PMID 39551862›Full record

ArticleScientific reports2024

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.

Jing Ma, Huiqiu Zhang, Junsen Zhao, Menghan Su, Yingna Feng, Xiaoli Yuan, Dan Liu, Xiaomin Pang, Rongjuan Zhao, Juan Wang and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. FcRn inhibitors for myasthenia gravis.The Cochrane database of systematic reviews · 2025
    Article
  14. New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jing MaDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Huiqiu ZhangDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Junsen ZhaoDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Menghan SuDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Yingna FengDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Xiaoli YuanDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Dan LiuDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Xiaomin PangDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Rongjuan ZhaoDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Juan WangDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Weisong DuanDepartment of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xueli ChangDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China.
Junhong GuoDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China. neuroguo@163.com.
Wei ZhangDepartment of Neurology, First Hospital of Shanxi Medical University, No.85, Jiefang South Street, Taiyuan, China. zhangvey@126.com.

Funding

Shanxi Science and Technology Department 20210302123245the Founding of Health Commission of Shanxi Province 2019034
6 · The paper itself

Abstract

Impending myasthenic crisis (IMC) is an emergent situation requiring aggressive management to prevent patients from developing myasthenic crisis (MC) in patients with myasthenia gravis (MG). Efgartigimod has been proved to be well tolerated and efficacious in MG patients. The present study aimed to compare the efficacy of efgartigimod and intravenous immunoglobulin (IVIg) in rescuing IMC. IMC patients treated with efgartigimod or IVIg were retrospectively enrolled. The primary outcome was determined as the mean change in MG activities of daily living (MG-ADL) score from baseline to week 1 and 4 after treatment, respectively. Safety was assessed based on medical records during the hospitalization to monitor the adverse events. A total of 9 patients treated with efgartigimod and 10 patients treated with IVIg were enrolled. There were no significant differences in the clinical characteristics at baseline between the two groups (P > 0.05). Compared with the IVIg group, the efgartigimod group had a greater reduction in the MG-ADL score at week 1 (P = 0.035) and week 4 (P = 0.005). One patient in the efgartigimod group had an upper respiratory infection. These findings suggest that efgartigimod is a treatment option for IMC in addition to IVIg and plasma exchange.

Indexed as

Immunoglobulins, IntravenousMyasthenia GravisActivities of Daily LivingAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmunoglobulins, IntravenousEfficacyEfgartigimodImpending myasthenic crisisIVIgMyasthenia gravis

Identifiers

PMID39551862
PMCPMC11570634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.